The Cross-Border Biotech Blog

Rumoured Omeros IPO Might Signal Newly Opened Window

August 27, 2009 · Leave a Comment

light at the end of the tunnel smallAn article in Xconomy Seattle today reports rumours that Omeros, a company that has been around since 1996 and has raised over $102 million in private money, may revive its 2008 IPO plans.

The company’s lead products — “proprietary low-dose combinations of existing drugs” — are more pharma than biotech, putting it in line with Cumberland’s recent IPO.  However, Omeros also has a pipeline of preclinical CNS and inflammation molecules, so if its IPO succeeds, it may indicate that the public markets are truly (despite some skepticism) opening again to biotechs.

Bookmark and Share

Categories: Jeremy Grushcow · News
Tagged: , , ,

0 responses so far ↓

  • There are no comments yet...Kick things off by filling out the form below.

Leave a Comment